RecruitingNot ApplicableNCT06606366
Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA
Sponsor
Centre Antoine Lacassagne
Enrollment
238 participants
Start Date
Mar 3, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Over 18 years old.
- Advanced-stage malignant solid tumor managed in a non-curative context.
- Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.
- Performance status of 0 or 1.
- Patient able to read, write, and understand the French language.
- Patient has read the information sheet and signed the informed consent.
- Patient has social security coverage.
Exclusion Criteria8
- Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.
- Severe or uncontrolled systemic disease.
- Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.
- Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8:
- Pregnant women, women in labor, and breastfeeding mothers,
- Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8,
- Persons admitted to a healthcare or social institution for reasons other than research,
- Adults unable to give their consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREBlood sample taken for the liquid biopsy
36 mL will be taken for the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06606366
Related Trials
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT0720911143 locations
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
NCT039113883 locations
Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.
NCT067824511 location
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
NCT065751271 location
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
NCT062386871 location